Primary biliary cholangitis, or primary biliary cirrhosis, is a chronic and serious condition. When diagnosed, people with ...

Primary biliary cholangitis is a disease affecting the bile made by your liver. Here’s what to know about the causes, symptoms, treatment, and outlook.

GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking ...

A primary biliary cholangitis (PBC) diagnosis can be life-changing. For many, it’s an emotional journey filled with questions, uncertainties and a need to redefine what life looks like with a ...

Primary biliary cholangitis, or PBC, can cause damage to the bile ducts and liver. There is currently no cure for the disease. Learn more here.

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

BioWorld Content on 'primary biliary cholangitis' Intercept Pharmaceuticals Inc. lost its uphill battle to convince the U.S. FDA’s Gastrointestinal Drugs Advisory Committee that the risks of its ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

ID. Abstract Title. PBC. THU-291. Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus ...

Primary Biliary Cholangitis Market. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ...